Juniper Pharmaceuticals Says Merck, Germany, Gets Japan's Regulatory Approval For OneCrinone

Juniper Pharmaceuticals, Inc. JNP revealed that Merck KGaA, Darmstadt, Germany has got the approval of the regulator for its OneCrinone 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment. The approval is meant for the Japanese market.

Juniper's CEO, Frank Condella, said, "This approval further expands the global Crinone progesterone gel franchise into the world's' third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support. We look forward to supporting the launch of OneCrinone® in Japan later this year."

Merck Germany, has worldwide marketing rights to Crinone except the America, where Crinone is marketed by Allergan, Inc. AGN.

The stock shed 0.57 percent on Friday.